Updated: Lilly boosts sales guidance by $2B, but GLP-1 supply constraints still a focus

Eli Lil­ly is ex­pect­ing sup­ply dis­rup­tions for its block­buster weight loss and di­a­betes prod­ucts to con­tin­ue through the end of this year, ex­ec­u­tives told in­vestors.

Dur­ing its first-quar­ter earn­ings call on Tues­day, the com­pa­ny said it’s rapid­ly ex­pand­ing its man­u­fac­tur­ing ca­pac­i­ty, with six sites cur­rent­ly un­der con­struc­tion or ramp­ing up, and a sev­enth it re­cent­ly pur­chased. CFO Anat Ashke­nazi ex­pects Lil­ly to pro­duce 1.5-times more dos­es of its in­cretin med­i­cines in the sec­ond half of 2024 com­pared to the same pe­ri­od in 2023.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.